Alvotech Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $593M+20.5% YoYTTM through 31 Dec 2025
Net Income $27.9MTTM through 31 Dec 2025
Free Cash Flow -$114.7MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 61.0% |
| Operating Margin | 13.2% |
| Net Margin | 4.7% |
Returns
-9.8%ROE
1.9%ROA
3.5%ROIC
Balance Sheet Health
Debt / Equity-5.10x
Current Ratio1.89x
Net Debt$1.3B
Cash & Equivalents$172.4M
Quality Metrics
Piotroski F-Score3 / 9
FCF Margin-19.3%
Rule of 40-8.7
Earnings-Beat Rate50.0%
Multi-Year Trend
Diluted EPSFY2025: $0.10
Dividend
No dividend
Capital Allocation
Capex Intensity10.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Product Revenue | View detailsDriven by biosimilar launches including Selarsdi (referencing Stelara) in the US and AVT02 (referencing Humira) globally. | ||
| License and Other Revenue | View detailsGrew 43% year-on-year, driven by milestone achievements and licensing agreements with global commercial partners. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.